Effect of Cytochrome P450 2C19 681G>A Polymorphism on Premature Coronary Heart Disease

CLINICAL RESEARCH
Zhong-Hai Chi, Yuan-Yuan Li, Juan Li, Zheng Zhang*, Li Jia

The Affiliated Hospital of Medical College Qingdao University, Qingdao, China

*Corresponding author: Zheng Zhang, Graduate student from Medical College Qingdao University; Qingdao, China. E-mail: 163zhangz@163.com

Published: June 25, 2015. DOI: 10.21103/Article5(2)_CR1

Abstract: 

Objective: The aim of our study was to evaluate the association between cytochrome P450 2C19 (CYP2C19) 681G>A polymorphisms and the age of development of coronary heart disease. Additionally, the study might find some biological indicators at the gene level that could help to predict and evaluate the risk of coronary heart disease in time.  

Methods: This study included 352 individuals with coronary heart disease. Polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) was used to identify CYP2C19 681G>A. The objects were divided into wild type (GG or homozygous CYP2C19*1 wild-type) and mutant type (GA/AA or the mutant CYP2C19*2 allele) on the basis of genotype. The association between CYP2C19 gene polymorphism and the age of onset of coronary heart disease was assessed by multivariate linear regression analysis. 

Results: There was a significant association in the age of onset between the two groups (t=3.398, P=0.001), which was 58.51±12.72 years in the wild type and 53.95±11.63 years in the mutant group. The frequency of CYP2C19 681A (CYP2C19*2 allele) was 0.32, 0.268, 0.227 in different age groups, which was significantly different (χ2=10.745, P=0.005) in different groups, as well as in the genotype. The result, assessed by multiple linear regression, showed that genotype, smoking, obesity, and hyperlipidemia affect the age of onset of coronary heart disease (β was -0.167, 0.156, 0.155, and 0.112, P<0.05),  and mutually affect the age of onset of coronary heart disease. 

Conclusion: The study suggests that CYP2C19 681G>A  gene polymorphism may be one of the risk factors in susceptibility to early onset of coronary heart disease, but not an independent factor because other factors may play a synergistic role.

Keywords: 
CYP2C19 681G>A polymorphism; premature coronary heart disease; age of onset.
References: 
  1. Zhou X, Zhang JZ, Qi HZ, et al. Progress in cardiovascular drug metabolic enzyme and pharmacogenetic studies. China Pharm 2012; 23(26):2476-2479.
  2. Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 2000; 21(3):193-9.
  3. Ercan B, Ayaz L, Ciçek D, Tamer L..Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct 2008; 26 (3):309-13. Cell Biochem Funct 2008; 26 (3):309-13.
  4. Motulsky V. Human genetics. The third edition. Beijing; People's Medical Publishing House 1999:749-750.
  5. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle- income countries. Curr Probl Cardiol 2010; 35(2):72–115.
  6. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Eng1 J Med 2007; 356(16): 1620-30.
  7. Zhou B, Wu KX, Li Y, et al. Analysis of 236 cases of coronary angiography in patients with clinical background information. Chin J Prac Diag Treat,2008; 22(11):872-3.
  8. Han Y, Xu W, Zhang W, Liu N, Ji Y.. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology 2010; 85(4):211–6.
  9. Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev2007; 6(2): 94–108.
  10. Elbekai RH, EI-Kadi AO. Cytochrome P450 enzymes：central players in cardiovascular health and disease. Pharmacol Ther 2006; 112(2):564-87.
  11. Zhan TY, Shi Lei, Zhao SJ, et al. The correlation between the CYP2J2* 7 gene polymorphism and coronary heart disease in Chinese Han population. Guangdong Med J 2011; 32(12):1543-5．
  12. He BX, Shi L, Qiu J, Tao L, Li R, Yang L, Zhao SJ. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol 2011;108(3): 208-13．
  13. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108(7):2244-7.
  14. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51(20):1925-34.
  15. Xiao YF, Huang L, Morgan JP. Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 1998;508(Pt3):777−92.
  16. Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450 dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8(5):315−9.
  17. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther, 2006, 112(2):564–87.
  18. Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics, 2007 ; 17(9):731-42.
  19. Wang Q, Zhang GJ, Kang XX. Effects of CYP2C19 gene polymorphisms on clopidogrel metabolism [J/CD]. Chin J Clin (Electronic Edition). 2013;7(21):9746-9.
  20. Kral BG, Becker DM, Vaidya D, Yanek LR, Becker LC. Severity of inducible myocardial ischemia predicts incident acute coronary syndromes in asymptomatic individuals with a family hospital of premature coronary artery disease. J Nucl Cardiol 2012; 19(1):28-36.
  21. Chu YR, Chu ZH, Zhu YL, Research on the relationship between apolipoprotein E gene polymorphism and early-onset coronary heart disease. Prog Mod Biomed 2007; 7(2):244-6.
  22. Sun JG, Zhang XL, Hu JP. Sexual difference of clinical characteristics in premature coronary heart disease patients. Anhui Med J 2011; 32(2):213-5.
  23. Yang JL, Yang FY. Risk factors for coronary heart disease and Prevention. PJCCPVD 2010; 18(7):1014-5.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2015; 5(2):55-59. © 2015 International Medical Research and Development Corporation. All rights reserved.